Research programme: kidney disorder therapeutics - Angiotensin Therapeutics
Latest Information Update: 19 Feb 2021
At a glance
- Originator Northwestern University
- Developer Angiotensin Therapeutics
- Class Enzymes; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute kidney injury; Renal failure
Most Recent Events
- 04 Feb 2021 Kidney disorder therapeutics - Angiotensin Therapeutics is available for licensing as of 04 Feb 2021. https://angiotx.com/about/investors/
- 04 Feb 2021 Preclinical trials in Acute kidney injury in USA (Parenteral)
- 04 Feb 2021 Preclinical trials in Renal failure in USA (Parenteral)